0|chunk|Open Peer Review Targeting viral entry as a strategy for broad-spectrum antivirals [version 1; peer review: 3 approved] v1
0	72	82 antivirals	Chemical	CHEBI_22587

1|chunk|F1000 Faculty Reviews are written by members of the prestigious . They are F1000 Faculty commissioned and are peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

2|chunk|The process of entry into a host cell is a key step in the life cycle of most viruses. In recent years, there has been a significant increase in our understanding of the routes and mechanisms of entry for a number of these viruses. This has led to the development of novel broad-spectrum antiviral approaches that target host cell proteins and pathways, in addition to strategies focused on individual viruses or virus families. Here we consider a number of these approaches and their broad-spectrum potential. PubMed Abstract | Publisher Full Text 2. Mercer J, Schelhaas M, Helenius A: Virus entry by endocytosis. Annu Rev Biochem. 2010; 79: 803-33. PubMed Abstract | Publisher Full Text 3. Snchez-San Martn C, Liu CY, Kielian M: Dealing with low pH: entry and exit of alphaviruses and flaviviruses. Trends Microbiol. 2009; 17(11): 514-21. PubMed Abstract | Publisher Full Text | Free Full Text 4. Mercer J, Helenius A: Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science. 2008; 320(5875): 531-5. PubMed Abstract | Publisher Full Text | F1000 Recommendation 5. Moller-Tank S, Maury W: Ebola virus entry: a curious and complex series of events. PLoS Pathog. 2015; 11(4): e100473. PubMed Abstract | Publisher Full Text | Free Full Text 6. Saeed MF, Kolokoltsov AA, Albrecht T, et al.: Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog. 2010; 6(9): e1001110. PubMed Abstract | Publisher Full Text | Free Full Text 7. WuDunn D, Spear PG: Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J Virol. 1989; 63(1): 52-8. PubMed Abstract | Free Full Text 8. Giroglou T, Florin L, Schfer F, et al.: Human papillomavirus infection requires cell surface heparan sulfate. J Virol. 2001; 75(3): 1565-70. PubMed Abstract | Publisher Full Text | Free Full Text 9. Feldman SA, Hendry RM, Beeler JA: Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. J Virol. 1999; 73(8): 6610-7. PubMed Abstract | Free Full Text 10. Klimyte EM, Smith SE, Oreste P, et al.: Inhibition of Human Metapneumovirus Binding to Heparan Sulfate Blocks Infection in Human Lung Cells and Airway Tissues. J Virol. 2016; 90(20): 9237-50. PubMed Abstract | Publisher Full Text | Free Full Text 11. Collett MS, Hincks JR, Benschop K, et al.: Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model. J Infect Dis. 2017; 215(3): 335-343.
2	288	297 antiviral	Chemical	CHEBI_22587
2	331	339 proteins	Chemical	CHEBI_36080
2	1648	1655 heparan	Chemical	CHEBI_24500
2	1648	1663 heparan sulfate	Chemical	CHEBI_28815
2	1656	1663 sulfate	Chemical	CHEBI_16189
2	1823	1830 heparan	Chemical	CHEBI_24500
2	1823	1838 heparan sulfate	Chemical	CHEBI_28815
2	1831	1838 sulfate	Chemical	CHEBI_16189
2	1990	1997 heparin	Chemical	CHEBI_28304
2	2062	2074 glycoprotein	Chemical	CHEBI_17089
2	2232	2239 Heparan	Chemical	CHEBI_24500
2	2232	2247 Heparan Sulfate	Chemical	CHEBI_28815
2	2240	2247 Sulfate	Chemical	CHEBI_16189
2	2439	2448 Antiviral	Chemical	CHEBI_22587
2	CHEBI-CHEBI	CHEBI_22587	CHEBI_36080
2	CHEBI-CHEBI	CHEBI_22587	CHEBI_24500
2	CHEBI-CHEBI	CHEBI_22587	CHEBI_28815
2	CHEBI-CHEBI	CHEBI_22587	CHEBI_16189
2	CHEBI-CHEBI	CHEBI_22587	CHEBI_28304
2	CHEBI-CHEBI	CHEBI_22587	CHEBI_17089
2	CHEBI-CHEBI	CHEBI_36080	CHEBI_24500
2	CHEBI-CHEBI	CHEBI_36080	CHEBI_28815
2	CHEBI-CHEBI	CHEBI_36080	CHEBI_16189
2	CHEBI-CHEBI	CHEBI_36080	CHEBI_28304
2	CHEBI-CHEBI	CHEBI_36080	CHEBI_17089
2	CHEBI-CHEBI	CHEBI_24500	CHEBI_28815
2	CHEBI-CHEBI	CHEBI_24500	CHEBI_16189
2	CHEBI-CHEBI	CHEBI_24500	CHEBI_28304
2	CHEBI-CHEBI	CHEBI_24500	CHEBI_17089
2	CHEBI-CHEBI	CHEBI_28815	CHEBI_16189
2	CHEBI-CHEBI	CHEBI_28815	CHEBI_28304
2	CHEBI-CHEBI	CHEBI_28815	CHEBI_17089
2	CHEBI-CHEBI	CHEBI_16189	CHEBI_28304
2	CHEBI-CHEBI	CHEBI_16189	CHEBI_17089
2	CHEBI-CHEBI	CHEBI_28304	CHEBI_17089

3|chunk|PubMed Abstract | Publisher Full Text | Free Full Text 12. Ghosh T, Chattopadhyay K, Marschall M, et al.: Focus on antivirally active sulfated polysaccharides: from structure-activity analysis to clinical evaluation. Glycobiology. 2009; 19(1): 2-15. PubMed Abstract | Publisher Full Text 13. Lee E, Pavy M, Young N, et al.: Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses. Antiviral Res. 2006; 69(1): 31-8. PubMed Abstract | Publisher Full Text 14. Cagno V, Andreozzi P, D'Alicarnasso M, et al.: Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism. Nat Mater. 2018; 17(2): 195-203. PubMed Abstract | Publisher Full Text | F1000 Recommendation 15. Botos I, Wlodawer A: Cyanovirin-N: a sugar-binding antiviral protein with a new twist. Cell Mol Life Sci. 2003; 60(2): 277-87. PubMed Abstract | Publisher Full Text 16. Barrientos LG, O'Keefe BR, Bray M, et al.: Cyanovirin-N binds to the viral surface glycoprotein, GP 1,2 and inhibits infectivity of Ebola virus. Antiviral Res. 2003; 58(1): 47-56. PubMed Abstract | Publisher Full Text 17. Zhou Y, Simmons G: Development of novel entry inhibitors targeting emerging viruses. Expert Rev Anti Infect Ther. 2012; 10(10): 1129-38. PubMed Abstract | Publisher Full Text | Free Full Text 18. Carette JE, Raaben M, Wong AC, et al.: Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature. 2011; 477(7364): 340-3. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 19. Malakhov MP, Aschenbrenner LM, Smee DF, et al.: Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother. 2006; 50(4): 1470-9. PubMed Abstract | Publisher Full Text | Free Full Text 20. Moss RB, Hansen C, Sanders RL, et al.: A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis. 2012; 206(12): 1844-51. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 21. Li F, Ma C, Wang J: Inhibitors targeting the influenza virus hemagglutinin. Curr Med Chem. 2015; 22(11): 1361-82. PubMed Abstract | Publisher Full Text 22. MacArthur RD, Novak RM: Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis. 2008; 47(2): 236-41. PubMed Abstract | Publisher Full Text 23. Dorr P, Westby M, Dobbs S, et al.: Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005; 49(11): 4721-32. PubMed Abstract | Publisher Full Text | Free Full Text 24. Pastore C, Ramos A, Mosier DE: Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J Virol. 2004; 78(14): 7565-74. PubMed Abstract | Publisher Full Text | Free Full Text 25. Vermeire K, Bell TW, van Puyenbroeck V, et al.: Signal peptide-binding drug as a selective inhibitor of co-translational protein translocation. PLoS Biol. 2014; 12(12): e1002011. PubMed Abstract | Publisher Full Text | Free Full Text 26. van Dongen MJP, Kadam RU, Juraszek J, et al.: A small-molecule fusion inhibitor of influenza virus is orally active in mice. Science. 2019; 363(641): pii: eaar6221. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 27. Jae LT, Raaben M, Herbert AS, et al.: Virus entry. Lassa virus entry requires a trigger-induced receptor switch. Science. 2014; 344(6191): 1506-10. PubMed Abstract | Publisher Full Text | Free Full Text 28. Wec AZ, Nyakatura EK, Herbert AS, et al.: A "Trojan horse" bispecificantibody strategy for broad protection against ebolaviruses. Science. 2016; 354(6310): 350-4. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 29. Fabozzi G, Pegu A, Koup RA, et al.: Bispecific antibodies: Potential immunotherapies for HIV treatment. Methods. 2019; 154: 118-24. PubMed Abstract | Publisher Full Text | Free Full Text 30. Ct M, Misasi J, Ren T, et al.: Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature. 2011; 477(7364): 344-8. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 31. Buontempo PJ, Cox S, Wright-Minogue J, et al.: SCH 48973: a potent, broadspectrum, antienterovirus compound. Antimicrob Agents Chemother. 1997; 41(6): 1220-5. PubMed Abstract | Publisher Full Text | Free Full Text 32. Torres-Torres S, Myers AL, Klatte JM, et al.: First use of investigational antiviral drug pocapavir (v-073) for treating neonatal enteroviral sepsis. Pediatr Infect Dis J. 2015; 34(1): 52-4. PubMed Abstract | Publisher Full Text 33. Smith TJ, Kremer MJ, Luo M, et al.: The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science. 1986; 233(4770): 1286-93. PubMed Abstract | Publisher Full Text 34. Abdelnabi R, Geraets JA, Ma Y, et al.: A novel druggable interprotomer pocket in the capsid of rhino-and enteroviruses. PLoS Biol. 2019; 17(6): e3000281. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 35. Sun L, Lee H, Thibaut HJ, et al.: Viral engagement with host receptors blocked by a novel class of tryptophan dendrimers that targets the 5-fold-axis of the enterovirus-A71 capsid. PLoS Pathog. 2019; 15(5): e1007760. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 36. Diehl N, Schaal H: Make yourself at home: viral hijacking of the PI3K/Akt signaling pathway. Viruses. 2013; 5(12): 3192-212. PubMed Abstract | Publisher Full Text | Free Full Text 37. Mazzon M, Castro C, Thaa B, et al.: Alphavirus-induced hyperactivation of PI3K/ AKT directs pro-viral metabolic changes. PLoS Pathog. 2018; 14(1): e1006835. PubMed Abstract | Publisher Full Text | Free Full Text 38. Mercer J, Knbel S, Schmidt FI, et al.: Vaccinia virus strains use distinct forms of macropinocytosis for host-cell entry. Proc Natl Acad Sci U S A. 2010; 107(20): 9346-51. PubMed Abstract | Publisher Full Text | Free Full Text 39. Dutta D, Williamson CD, Cole NB, et al.: Pitstop 2 is a potent inhibitor of clathrinindependent endocytosis. PLoS One. 2012; 7(9): e45799. PubMed Abstract | Publisher Full Text | Free Full Text 40. Macia E, Ehrlich M, Massol R, et al.: Dynasore, a cell-permeable inhibitor of dynamin. Dev Cell. 2006; 10(6): 839-50. PubMed Abstract | Publisher Full Text | F1000 Recommendation 41. McCluskey A, Daniel JA, Hadzic G, et al.: Building a better dynasore: the dyngo compounds potently inhibit dynamin and endocytosis. Traffic. 2013; 14(12): 1272-89. PubMed Abstract | Publisher Full Text | Free Full Text 42. Harper CB, Martin S, Nguyen TH, et al.: Dynamin inhibition blocks botulinum neurotoxin type A endocytosis in neurons and delays botulism. J Biol Chem. 2011; 286(41): 35966-76. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 43. de Wilde AH, Jochmans D, Posthuma CC, et al.: Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014; 58(8): 4875-84. PubMed Abstract | Publisher Full Text | Free Full Text 44. Blaising J, Lvy PL, Polyak SJ, et al.: Arbidol inhibits viral entry by interfering PubMed Abstract | Publisher Full Text 45. Mazzon M, Ortega-Prieto AM, Imrie D, et al.: Identification of Broad-Spectrum Antiviral Compounds by Targeting Viral Entry. Viruses. 2019; 11(2): pii: E176. PubMed Abstract | Publisher Full Text | Free Full Text 46. Banbury DN, Oakley JD, Sessions RB, et al.: Tyrphostin A23 inhibits internalization of the transferrin receptor by perturbing the interaction between tyrosine motifs and the medium chain subunit of the AP-2 adaptor complex. J Biol Chem. 2003; 278(14): 12022-8. PubMed Abstract | Publisher Full Text 47. Dejonghe W, Kuenen S, Mylle E, et al.: Mitochondrial uncouplers inhibit clathrinmediated endocytosis largely through cytoplasmic acidification. Nat Commun. 2016; 7: 11710. PubMed Abstract | Publisher Full Text | Free Full Text 48. Jurgeit A, McDowell R, Moese S, et al.: Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects. PLoS Pathog. 2012; 8(10): e1002976. PubMed Abstract | Publisher Full Text | Free Full Text 49. HAYES WJ, LAWS JR: Classes of pesticides. In: LAWS H. (ed.) Handbook of Pesticide Toxicology. New york, NY: Academic press. 1991. Publisher Full Text 50. Doms RW, Moore JP: HIV-1 membrane fusion: targets of opportunity. J Cell Biol. 2000; 151(2): F9-14. PubMed Abstract | Publisher Full Text | Free Full Text 51. Kaufmann SHE, Dorhoi A, Hotchkiss RS, et al.: Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov. 2018; 17(1): 35-56. PubMed Abstract | Publisher Full Text 52. Savarino A, Boelaert JR, Cassone A, et al.: Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 2003; 3(11): 722-7.
3	324	333 Antiviral	Chemical	CHEBI_22587
3	348	355 heparan	Chemical	CHEBI_24500
3	348	363 heparan sulfate	Chemical	CHEBI_28815
3	356	363 sulfate	Chemical	CHEBI_16189
3	426	435 Antiviral	Chemical	CHEBI_22587
3	574	583 antiviral	Chemical	CHEBI_22587
3	584	597 nanoparticles	Chemical	CHEBI_50803
3	637	640 Nat	Chemical	CHEBI_82508
3	786	795 antiviral	Chemical	CHEBI_22587
3	796	803 protein	Chemical	CHEBI_16541
3	1049	1058 Antiviral	Chemical	CHEBI_22587
3	1172	1182 inhibitors	Chemical	CHEBI_35222
3	1392	1403 cholesterol	Chemical	CHEBI_16113
3	1612	1619 protein	Chemical	CHEBI_16541
3	1646	1655 inhibitor	Chemical	CHEBI_35222
3	1884	1893 antiviral	Chemical	CHEBI_22587
3	2076	2086 Inhibitors	Chemical	CHEBI_35222
3	2137	2140 Med	Chemical	CHEBI_16867
3	2270	2279 maraviroc	Chemical	CHEBI_63608
3	2447	2456 Maraviroc	Chemical	CHEBI_63608
3	2531	2540 inhibitor	Chemical	CHEBI_35222
3	3024	3028 drug	Chemical	CHEBI_23888
3	3044	3053 inhibitor	Chemical	CHEBI_35222
3	3074	3081 protein	Chemical	CHEBI_16541
3	3261	3270 inhibitor	Chemical	CHEBI_35222
3	4120	4128 molecule	Chemical	CHEBI_25367
3	4129	4139 inhibitors	Chemical	CHEBI_35222
3	4610	4619 antiviral	Chemical	CHEBI_22587
3	4610	4624 antiviral drug	Chemical	CHEBI_36044
3	4620	4624 drug	Chemical	CHEBI_23888
3	4854	4863 antiviral	Chemical	CHEBI_22587
3	4854	4870 antiviral agents	Chemical	CHEBI_22587
3	5307	5317 tryptophan	Chemical	CHEBI_16828
3	5307	5317 tryptophan	Chemical	CHEBI_27897
3	6202	6211 inhibitor	Chemical	CHEBI_35222
3	6402	6411 inhibitor	Chemical	CHEBI_35222
3	6819	6829 neurotoxin	Chemical	CHEBI_50910
3	7124	7134 inhibitors	Chemical	CHEBI_35222
3	7362	7369 Arbidol	Chemical	CHEBI_134730
3	7526	7535 Antiviral	Chemical	CHEBI_22587
3	7708	7718 Tyrphostin	Chemical	CHEBI_38637
3	7814	7822 tyrosine	Chemical	CHEBI_17895
3	7814	7822 tyrosine	Chemical	CHEBI_18186
3	8111	8114 Nat	Chemical	CHEBI_82508
3	8238	8249 Niclosamide	Chemical	CHEBI_7553
3	8255	8261 proton	Chemical	CHEBI_24636
3	8262	8269 carrier	Chemical	CHEBI_78059
3	8310	8319 antiviral	Chemical	CHEBI_22587
3	8496	8505 Pesticide	Chemical	CHEBI_25944
3	8843	8846 Nat	Chemical	CHEBI_82508
3	8851	8855 Drug	Chemical	CHEBI_23888
3	8981	8992 chloroquine	Chemical	CHEBI_3638
3	9021	9025 drug	Chemical	CHEBI_23888
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_24500
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_28815
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_16189
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_50803
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_82508
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_16541
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_35222
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_16113
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_16867
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_63608
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_23888
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_25367
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_36044
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_16828
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_27897
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_50910
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_134730
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_38637
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_17895
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_7553
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_24636
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_78059
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_28815
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_16189
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_50803
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_82508
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_16541
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_35222
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_16113
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_16867
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_63608
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_23888
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_25367
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_36044
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_16828
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_27897
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_50910
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_134730
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_38637
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_17895
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_7553
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_24636
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_78059
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_24500	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_28815	CHEBI_16189
3	CHEBI-CHEBI	CHEBI_28815	CHEBI_50803
3	CHEBI-CHEBI	CHEBI_28815	CHEBI_82508
3	CHEBI-CHEBI	CHEBI_28815	CHEBI_16541
3	CHEBI-CHEBI	CHEBI_28815	CHEBI_35222
3	CHEBI-CHEBI	CHEBI_28815	CHEBI_16113
3	CHEBI-CHEBI	CHEBI_28815	CHEBI_16867
3	CHEBI-CHEBI	CHEBI_28815	CHEBI_63608
3	CHEBI-CHEBI	CHEBI_28815	CHEBI_23888
3	CHEBI-CHEBI	CHEBI_28815	CHEBI_25367
3	CHEBI-CHEBI	CHEBI_28815	CHEBI_36044
3	CHEBI-CHEBI	CHEBI_28815	CHEBI_16828
3	CHEBI-CHEBI	CHEBI_28815	CHEBI_27897
3	CHEBI-CHEBI	CHEBI_28815	CHEBI_50910
3	CHEBI-CHEBI	CHEBI_28815	CHEBI_134730
3	CHEBI-CHEBI	CHEBI_28815	CHEBI_38637
3	CHEBI-CHEBI	CHEBI_28815	CHEBI_17895
3	CHEBI-CHEBI	CHEBI_28815	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_28815	CHEBI_7553
3	CHEBI-CHEBI	CHEBI_28815	CHEBI_24636
3	CHEBI-CHEBI	CHEBI_28815	CHEBI_78059
3	CHEBI-CHEBI	CHEBI_28815	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_28815	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_16189	CHEBI_50803
3	CHEBI-CHEBI	CHEBI_16189	CHEBI_82508
3	CHEBI-CHEBI	CHEBI_16189	CHEBI_16541
3	CHEBI-CHEBI	CHEBI_16189	CHEBI_35222
3	CHEBI-CHEBI	CHEBI_16189	CHEBI_16113
3	CHEBI-CHEBI	CHEBI_16189	CHEBI_16867
3	CHEBI-CHEBI	CHEBI_16189	CHEBI_63608
3	CHEBI-CHEBI	CHEBI_16189	CHEBI_23888
3	CHEBI-CHEBI	CHEBI_16189	CHEBI_25367
3	CHEBI-CHEBI	CHEBI_16189	CHEBI_36044
3	CHEBI-CHEBI	CHEBI_16189	CHEBI_16828
3	CHEBI-CHEBI	CHEBI_16189	CHEBI_27897
3	CHEBI-CHEBI	CHEBI_16189	CHEBI_50910
3	CHEBI-CHEBI	CHEBI_16189	CHEBI_134730
3	CHEBI-CHEBI	CHEBI_16189	CHEBI_38637
3	CHEBI-CHEBI	CHEBI_16189	CHEBI_17895
3	CHEBI-CHEBI	CHEBI_16189	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_16189	CHEBI_7553
3	CHEBI-CHEBI	CHEBI_16189	CHEBI_24636
3	CHEBI-CHEBI	CHEBI_16189	CHEBI_78059
3	CHEBI-CHEBI	CHEBI_16189	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_16189	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_50803	CHEBI_82508
3	CHEBI-CHEBI	CHEBI_50803	CHEBI_16541
3	CHEBI-CHEBI	CHEBI_50803	CHEBI_35222
3	CHEBI-CHEBI	CHEBI_50803	CHEBI_16113
3	CHEBI-CHEBI	CHEBI_50803	CHEBI_16867
3	CHEBI-CHEBI	CHEBI_50803	CHEBI_63608
3	CHEBI-CHEBI	CHEBI_50803	CHEBI_23888
3	CHEBI-CHEBI	CHEBI_50803	CHEBI_25367
3	CHEBI-CHEBI	CHEBI_50803	CHEBI_36044
3	CHEBI-CHEBI	CHEBI_50803	CHEBI_16828
3	CHEBI-CHEBI	CHEBI_50803	CHEBI_27897
3	CHEBI-CHEBI	CHEBI_50803	CHEBI_50910
3	CHEBI-CHEBI	CHEBI_50803	CHEBI_134730
3	CHEBI-CHEBI	CHEBI_50803	CHEBI_38637
3	CHEBI-CHEBI	CHEBI_50803	CHEBI_17895
3	CHEBI-CHEBI	CHEBI_50803	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_50803	CHEBI_7553
3	CHEBI-CHEBI	CHEBI_50803	CHEBI_24636
3	CHEBI-CHEBI	CHEBI_50803	CHEBI_78059
3	CHEBI-CHEBI	CHEBI_50803	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_50803	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_82508	CHEBI_16541
3	CHEBI-CHEBI	CHEBI_82508	CHEBI_35222
3	CHEBI-CHEBI	CHEBI_82508	CHEBI_16113
3	CHEBI-CHEBI	CHEBI_82508	CHEBI_16867
3	CHEBI-CHEBI	CHEBI_82508	CHEBI_63608
3	CHEBI-CHEBI	CHEBI_82508	CHEBI_23888
3	CHEBI-CHEBI	CHEBI_82508	CHEBI_25367
3	CHEBI-CHEBI	CHEBI_82508	CHEBI_36044
3	CHEBI-CHEBI	CHEBI_82508	CHEBI_16828
3	CHEBI-CHEBI	CHEBI_82508	CHEBI_27897
3	CHEBI-CHEBI	CHEBI_82508	CHEBI_50910
3	CHEBI-CHEBI	CHEBI_82508	CHEBI_134730
3	CHEBI-CHEBI	CHEBI_82508	CHEBI_38637
3	CHEBI-CHEBI	CHEBI_82508	CHEBI_17895
3	CHEBI-CHEBI	CHEBI_82508	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_82508	CHEBI_7553
3	CHEBI-CHEBI	CHEBI_82508	CHEBI_24636
3	CHEBI-CHEBI	CHEBI_82508	CHEBI_78059
3	CHEBI-CHEBI	CHEBI_82508	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_82508	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_35222
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_16113
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_16867
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_63608
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_23888
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_25367
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_36044
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_16828
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_27897
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_50910
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_134730
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_38637
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_17895
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_7553
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_24636
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_78059
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_16113
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_16867
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_63608
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_23888
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_25367
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_36044
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_16828
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_27897
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_50910
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_134730
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_38637
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_17895
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_7553
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_24636
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_78059
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_16113	CHEBI_16867
3	CHEBI-CHEBI	CHEBI_16113	CHEBI_63608
3	CHEBI-CHEBI	CHEBI_16113	CHEBI_23888
3	CHEBI-CHEBI	CHEBI_16113	CHEBI_25367
3	CHEBI-CHEBI	CHEBI_16113	CHEBI_36044
3	CHEBI-CHEBI	CHEBI_16113	CHEBI_16828
3	CHEBI-CHEBI	CHEBI_16113	CHEBI_27897
3	CHEBI-CHEBI	CHEBI_16113	CHEBI_50910
3	CHEBI-CHEBI	CHEBI_16113	CHEBI_134730
3	CHEBI-CHEBI	CHEBI_16113	CHEBI_38637
3	CHEBI-CHEBI	CHEBI_16113	CHEBI_17895
3	CHEBI-CHEBI	CHEBI_16113	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_16113	CHEBI_7553
3	CHEBI-CHEBI	CHEBI_16113	CHEBI_24636
3	CHEBI-CHEBI	CHEBI_16113	CHEBI_78059
3	CHEBI-CHEBI	CHEBI_16113	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_16113	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_16867	CHEBI_63608
3	CHEBI-CHEBI	CHEBI_16867	CHEBI_23888
3	CHEBI-CHEBI	CHEBI_16867	CHEBI_25367
3	CHEBI-CHEBI	CHEBI_16867	CHEBI_36044
3	CHEBI-CHEBI	CHEBI_16867	CHEBI_16828
3	CHEBI-CHEBI	CHEBI_16867	CHEBI_27897
3	CHEBI-CHEBI	CHEBI_16867	CHEBI_50910
3	CHEBI-CHEBI	CHEBI_16867	CHEBI_134730
3	CHEBI-CHEBI	CHEBI_16867	CHEBI_38637
3	CHEBI-CHEBI	CHEBI_16867	CHEBI_17895
3	CHEBI-CHEBI	CHEBI_16867	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_16867	CHEBI_7553
3	CHEBI-CHEBI	CHEBI_16867	CHEBI_24636
3	CHEBI-CHEBI	CHEBI_16867	CHEBI_78059
3	CHEBI-CHEBI	CHEBI_16867	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_16867	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_63608	CHEBI_23888
3	CHEBI-CHEBI	CHEBI_63608	CHEBI_25367
3	CHEBI-CHEBI	CHEBI_63608	CHEBI_36044
3	CHEBI-CHEBI	CHEBI_63608	CHEBI_16828
3	CHEBI-CHEBI	CHEBI_63608	CHEBI_27897
3	CHEBI-CHEBI	CHEBI_63608	CHEBI_50910
3	CHEBI-CHEBI	CHEBI_63608	CHEBI_134730
3	CHEBI-CHEBI	CHEBI_63608	CHEBI_38637
3	CHEBI-CHEBI	CHEBI_63608	CHEBI_17895
3	CHEBI-CHEBI	CHEBI_63608	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_63608	CHEBI_7553
3	CHEBI-CHEBI	CHEBI_63608	CHEBI_24636
3	CHEBI-CHEBI	CHEBI_63608	CHEBI_78059
3	CHEBI-CHEBI	CHEBI_63608	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_63608	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_25367
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_36044
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_16828
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_27897
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_50910
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_134730
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_38637
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_17895
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_7553
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_24636
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_78059
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_25367	CHEBI_36044
3	CHEBI-CHEBI	CHEBI_25367	CHEBI_16828
3	CHEBI-CHEBI	CHEBI_25367	CHEBI_27897
3	CHEBI-CHEBI	CHEBI_25367	CHEBI_50910
3	CHEBI-CHEBI	CHEBI_25367	CHEBI_134730
3	CHEBI-CHEBI	CHEBI_25367	CHEBI_38637
3	CHEBI-CHEBI	CHEBI_25367	CHEBI_17895
3	CHEBI-CHEBI	CHEBI_25367	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_25367	CHEBI_7553
3	CHEBI-CHEBI	CHEBI_25367	CHEBI_24636
3	CHEBI-CHEBI	CHEBI_25367	CHEBI_78059
3	CHEBI-CHEBI	CHEBI_25367	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_25367	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_36044	CHEBI_16828
3	CHEBI-CHEBI	CHEBI_36044	CHEBI_27897
3	CHEBI-CHEBI	CHEBI_36044	CHEBI_50910
3	CHEBI-CHEBI	CHEBI_36044	CHEBI_134730
3	CHEBI-CHEBI	CHEBI_36044	CHEBI_38637
3	CHEBI-CHEBI	CHEBI_36044	CHEBI_17895
3	CHEBI-CHEBI	CHEBI_36044	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_36044	CHEBI_7553
3	CHEBI-CHEBI	CHEBI_36044	CHEBI_24636
3	CHEBI-CHEBI	CHEBI_36044	CHEBI_78059
3	CHEBI-CHEBI	CHEBI_36044	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_36044	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_16828	CHEBI_27897
3	CHEBI-CHEBI	CHEBI_16828	CHEBI_50910
3	CHEBI-CHEBI	CHEBI_16828	CHEBI_134730
3	CHEBI-CHEBI	CHEBI_16828	CHEBI_38637
3	CHEBI-CHEBI	CHEBI_16828	CHEBI_17895
3	CHEBI-CHEBI	CHEBI_16828	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_16828	CHEBI_7553
3	CHEBI-CHEBI	CHEBI_16828	CHEBI_24636
3	CHEBI-CHEBI	CHEBI_16828	CHEBI_78059
3	CHEBI-CHEBI	CHEBI_16828	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_16828	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_27897	CHEBI_50910
3	CHEBI-CHEBI	CHEBI_27897	CHEBI_134730
3	CHEBI-CHEBI	CHEBI_27897	CHEBI_38637
3	CHEBI-CHEBI	CHEBI_27897	CHEBI_17895
3	CHEBI-CHEBI	CHEBI_27897	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_27897	CHEBI_7553
3	CHEBI-CHEBI	CHEBI_27897	CHEBI_24636
3	CHEBI-CHEBI	CHEBI_27897	CHEBI_78059
3	CHEBI-CHEBI	CHEBI_27897	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_27897	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_50910	CHEBI_134730
3	CHEBI-CHEBI	CHEBI_50910	CHEBI_38637
3	CHEBI-CHEBI	CHEBI_50910	CHEBI_17895
3	CHEBI-CHEBI	CHEBI_50910	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_50910	CHEBI_7553
3	CHEBI-CHEBI	CHEBI_50910	CHEBI_24636
3	CHEBI-CHEBI	CHEBI_50910	CHEBI_78059
3	CHEBI-CHEBI	CHEBI_50910	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_50910	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_134730	CHEBI_38637
3	CHEBI-CHEBI	CHEBI_134730	CHEBI_17895
3	CHEBI-CHEBI	CHEBI_134730	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_134730	CHEBI_7553
3	CHEBI-CHEBI	CHEBI_134730	CHEBI_24636
3	CHEBI-CHEBI	CHEBI_134730	CHEBI_78059
3	CHEBI-CHEBI	CHEBI_134730	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_134730	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_38637	CHEBI_17895
3	CHEBI-CHEBI	CHEBI_38637	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_38637	CHEBI_7553
3	CHEBI-CHEBI	CHEBI_38637	CHEBI_24636
3	CHEBI-CHEBI	CHEBI_38637	CHEBI_78059
3	CHEBI-CHEBI	CHEBI_38637	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_38637	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_17895	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_17895	CHEBI_7553
3	CHEBI-CHEBI	CHEBI_17895	CHEBI_24636
3	CHEBI-CHEBI	CHEBI_17895	CHEBI_78059
3	CHEBI-CHEBI	CHEBI_17895	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_17895	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_18186	CHEBI_7553
3	CHEBI-CHEBI	CHEBI_18186	CHEBI_24636
3	CHEBI-CHEBI	CHEBI_18186	CHEBI_78059
3	CHEBI-CHEBI	CHEBI_18186	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_18186	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_7553	CHEBI_24636
3	CHEBI-CHEBI	CHEBI_7553	CHEBI_78059
3	CHEBI-CHEBI	CHEBI_7553	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_7553	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_24636	CHEBI_78059
3	CHEBI-CHEBI	CHEBI_24636	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_24636	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_78059	CHEBI_25944
3	CHEBI-CHEBI	CHEBI_78059	CHEBI_3638
3	CHEBI-CHEBI	CHEBI_25944	CHEBI_3638

4|chunk|PubMed Abstract | Publisher Full Text 53. Long J, Wright E, Molesti E, et al.: Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry [version 2; peer review: 2 approved]. F1000Res. 2015; 4: 30. PubMed Abstract | Publisher Full Text | Free Full Text 54. Nicholson KG, Wiselka MJ: Amantadine for influenza A. BMJ. 1991; 302(6774): 425-6. PubMed Abstract | Publisher Full Text | Free Full Text 55. Monto AS, Arden NH: Implications of Viral Resistance to Amantadine in Control of Influenza A. Clin Infect Dis. 1992; 15(2): 362-7. PubMed Abstract | Publisher Full Text 56. Schornberg K, Matsuyama S, Kabsch K, et al.: Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J Virol. 2006; 80(8): 4174-8. PubMed Abstract | Publisher Full Text | Free Full Text 57. Sakurai Y, Kolokoltsov AA, Chen CC, et al.: Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment. Science. 2015; 347(6225): 995-8. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 58. Xiao JH, Rijal P, Schimanski L, et al.: Characterization of Influenza Virus Pseudotyped with Ebolavirus Glycoprotein. J Virol. 2018; 92(4): pii: e00941-17. PubMed Abstract | Publisher Full Text | Free Full Text 59. Penny CJ, Vassileva K, Jha A, et al.: Mining of Ebola virus entry inhibitors identifies approved drugs as two-pore channel pore blockers. Biochim Biophys Acta Mol Cell Res. 2019; 1866(7): 1151-1161. PubMed Abstract | Publisher Full Text 78. Han Y, Mesplde T, Xu H, et al.: The antimalarial drug amodiaquine possesses anti-ZIKA virus activities J Med Virol. 2018; 90(5): 796-802. PubMed Abstract | Publisher Full Text 79. Vigant F, Lee J, Hollmann A, et al.: A Mechanistic Paradigm for Broad-Spectrum Antivirals that Target Virus-Cell Fusion. PLoS Pathog. 2013; 9(4): e1003297. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 80. Wolf MC, Freiberg AN, Zhang T, et al.: A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A. 2010; 107(7): 3157-62. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 81. Zhu JD, Meng W, Wang XJ, et al.: Broad-spectrum antiviral agents. Front Microbiol. 2015; 6: 517. PubMed Abstract | Publisher Full Text | Free Full Text 82. Lu DY, Wu HY, Yarla NS, et al.: HAART in HIV/AIDS Treatments: Future Trends. Infect Disord Drug Targets. 2018; 18(1): 15-22. PubMed Abstract | Publisher Full Text | F1000 Recommendation 83. Ford N, Shubber Z, Calmy A, et al.: Choice of Antiretroviral Drugs for Postexposure Prophylaxis for Adults and Adolescents: A Systematic Review. Clin Infect Dis. 2015; 60 Suppl 3: S170-S176. PubMed Abstract | Publisher Full Text 84. Kirby BJ, Symonds WT, Kearney BP, et al.: Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir. Clin Pharmacokinet. 2015; 54(7): 677-90. PubMed Abstract | Publisher Full Text 85. Bekerman E, Einav S: Infectious disease. Combating emerging viral threats. Science. 2015; 348(6232): 282-3. PubMed Abstract | Publisher Full Text | Free Full Text 86. Cross RW, Mire CE, Feldmann H, et al.: Post-exposure treatments for Ebola and Marburg virus infections. Nat Rev Drug Discov. 2018; 17: 413-34. PubMed Abstract | Publisher Full Text 87. de La Vega MA, Caleo G, Audet J, et al.: Ebola viral load at diagnosis associates with patient outcome and outbreak evolution. J Clin Invest. 2015; 125(12): 4421-8. PubMed Abstract | Publisher Full Text | Free Full Text 88. Thi EP, Lee ACH, Geisbert JB, et al.: Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA. Nat Microbiol. 2016; 1(10): 16142. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 89. Vaughn DW, Green S, Kalayanarooj S, et al.: Dengue Viremia Titer, Antibody Response Pattern, and Virus Serotype Correlate with Disease Severity. J Infect Dis. 2000; 181(1): 2-9. PubMed Abstract | Publisher Full Text 90. Dwek RA, Butters TD, Platt FM, et al.: Targeting glycosylation as a therapeutic approach. Nat Rev Drug Discov. 2002; 1(1): 65-75. PubMed Abstract | Publisher Full Text
4	79	88 Antiviral	Chemical	CHEBI_22587
4	341	351 Amantadine	Chemical	CHEBI_2618
4	513	523 Amantadine	Chemical	CHEBI_2618
4	675	679 Role	Chemical	CHEBI_50906
4	963	967 drug	Chemical	CHEBI_23888
4	1395	1405 inhibitors	Chemical	CHEBI_35222
4	1426	1431 drugs	Chemical	CHEBI_23888
4	1607	1619 antimalarial	Chemical	CHEBI_38068
4	1620	1624 drug	Chemical	CHEBI_23888
4	1625	1636 amodiaquine	Chemical	CHEBI_131327
4	1676	1679 Med	Chemical	CHEBI_16867
4	1830	1840 Antivirals	Chemical	CHEBI_22587
4	2045	2054 antiviral	Chemical	CHEBI_22587
4	2272	2281 antiviral	Chemical	CHEBI_22587
4	2471	2475 Drug	Chemical	CHEBI_23888
4	2631	2636 Drugs	Chemical	CHEBI_23888
4	2949	2958 Inhibitor	Chemical	CHEBI_35222
4	3325	3328 Nat	Chemical	CHEBI_82508
4	3333	3337 Drug	Chemical	CHEBI_23888
4	3743	3748 lipid	Chemical	CHEBI_18059
4	3769	3772 Nat	Chemical	CHEBI_82508
4	4196	4199 Nat	Chemical	CHEBI_82508
4	4204	4208 Drug	Chemical	CHEBI_23888
4	CHEBI-CHEBI	CHEBI_22587	CHEBI_2618
4	CHEBI-CHEBI	CHEBI_22587	CHEBI_50906
4	CHEBI-CHEBI	CHEBI_22587	CHEBI_23888
4	CHEBI-CHEBI	CHEBI_22587	CHEBI_35222
4	CHEBI-CHEBI	CHEBI_22587	CHEBI_38068
4	CHEBI-CHEBI	CHEBI_22587	CHEBI_131327
4	CHEBI-CHEBI	CHEBI_22587	CHEBI_16867
4	CHEBI-CHEBI	CHEBI_22587	CHEBI_82508
4	CHEBI-CHEBI	CHEBI_22587	CHEBI_18059
4	CHEBI-CHEBI	CHEBI_2618	CHEBI_50906
4	CHEBI-CHEBI	CHEBI_2618	CHEBI_23888
4	CHEBI-CHEBI	CHEBI_2618	CHEBI_35222
4	CHEBI-CHEBI	CHEBI_2618	CHEBI_38068
4	CHEBI-CHEBI	CHEBI_2618	CHEBI_131327
4	CHEBI-CHEBI	CHEBI_2618	CHEBI_16867
4	CHEBI-CHEBI	CHEBI_2618	CHEBI_82508
4	CHEBI-CHEBI	CHEBI_2618	CHEBI_18059
4	CHEBI-CHEBI	CHEBI_50906	CHEBI_23888
4	CHEBI-CHEBI	CHEBI_50906	CHEBI_35222
4	CHEBI-CHEBI	CHEBI_50906	CHEBI_38068
4	CHEBI-CHEBI	CHEBI_50906	CHEBI_131327
4	CHEBI-CHEBI	CHEBI_50906	CHEBI_16867
4	CHEBI-CHEBI	CHEBI_50906	CHEBI_82508
4	CHEBI-CHEBI	CHEBI_50906	CHEBI_18059
4	CHEBI-CHEBI	CHEBI_23888	CHEBI_35222
4	CHEBI-CHEBI	CHEBI_23888	CHEBI_38068
4	CHEBI-CHEBI	CHEBI_23888	CHEBI_131327
4	CHEBI-CHEBI	CHEBI_23888	CHEBI_16867
4	CHEBI-CHEBI	CHEBI_23888	CHEBI_82508
4	CHEBI-CHEBI	CHEBI_23888	CHEBI_18059
4	CHEBI-CHEBI	CHEBI_35222	CHEBI_38068
4	CHEBI-CHEBI	CHEBI_35222	CHEBI_131327
4	CHEBI-CHEBI	CHEBI_35222	CHEBI_16867
4	CHEBI-CHEBI	CHEBI_35222	CHEBI_82508
4	CHEBI-CHEBI	CHEBI_35222	CHEBI_18059
4	CHEBI-CHEBI	CHEBI_38068	CHEBI_131327
4	CHEBI-CHEBI	CHEBI_38068	CHEBI_16867
4	CHEBI-CHEBI	CHEBI_38068	CHEBI_82508
4	CHEBI-CHEBI	CHEBI_38068	CHEBI_18059
4	CHEBI-CHEBI	CHEBI_131327	CHEBI_16867
4	CHEBI-CHEBI	CHEBI_131327	CHEBI_82508
4	CHEBI-CHEBI	CHEBI_131327	CHEBI_18059
4	CHEBI-CHEBI	CHEBI_16867	CHEBI_82508
4	CHEBI-CHEBI	CHEBI_16867	CHEBI_18059
4	CHEBI-CHEBI	CHEBI_82508	CHEBI_18059

